• Information
    • Welcome Message
    • Committees
    • WCLC 2020 Virtual FAQ’s
    • CME Information
      • Disclosures
      • CME Credit & Certificates
    • Important Dates
  • Program
    • Full Session Information
      Now Incl. Abstracts
    • Program at a Glance
    • Industry and Satellite CME Symposia
    • Product Showcase Theater
    • Presenter Resources
    • Virtual Presidential Symposium (August)
  • Advertising,
    Promotion & Exhibits
    • Promotion & Advertising
    • Exhibits
  • Press & Media
  • Registration
    Now Closed
  • Access the
    Recordings
    • Welcome Message
    • Committees
    • WCLC 2020 Virtual FAQ’s
    • CME Information
    • Disclosures
    • CME Credit & Certificates
    • Important Dates
    • Call for Abstracts
    • Education Awards
    • Presenter Resources
    • Registration
    • Promotion & Advertising
    • Exhibits
    • Full Session Information
      Now Incl. Abstracts
    • Program at a Glance
    • Industry and Satellite CME Symposia
    • Product Showcase Theater
    • Presenter Resources
    • Virtual Presidential Symposium (August)
    • Press & Media
    • Awards
MENU
  • Join Mailing List
  • IASLC.org
  • Contact Us
  • Information
    • Welcome Message
    • Committees
    • WCLC 2020 Virtual FAQ’s
    • CME Information
      • Disclosures
      • CME Credit & Certificates
    • Important Dates
  • Program
    • Full Session Information
      Now Incl. Abstracts
    • Program at a Glance
    • Industry and Satellite CME Symposia
    • Product Showcase Theater
    • Presenter Resources
    • Virtual Presidential Symposium (August)
  • Advertising,
    Promotion & Exhibits
    • Promotion & Advertising
    • Exhibits
  • Press & Media
  • Registration
    Now Closed
  • Access the
    Recordings
  • Join Mailing List
  • IASLC.org
  • Contact Us
  • #WCLC20
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
Conquering Thoracic Cancers Worldwide
  • Information
    • Welcome Message
    • Committees
    • WCLC 2020 Virtual FAQ’s
    • CME Information
      • Disclosures
      • CME Credit & Certificates
    • Important Dates
  • Program
    • Full Session Information
      Now Incl. Abstracts
    • Program at a Glance
    • Industry and Satellite CME Symposia
    • Product Showcase Theater
    • Presenter Resources
    • Virtual Presidential Symposium (August)
  • Advertising,
    Promotion & Exhibits
    • Promotion & Advertising
    • Exhibits
  • Press & Media
  • Registration
    Now Closed
  • Access the
    Recordings
Get Tickets!

INDUSTRY AND SATELLITE CME SYMPOSIA

  • Full Session Information
    Now Incl. Abstracts
  • Program at a Glance
  • Industry and Satellite CME Symposia
  • Product Showcase Theater
  • Presenter Resources
  • Virtual Presidential Symposium (August)

Tweets by IASLC

To view the Industry & Satellite CME Symposia schedule, please select the destination that is closest to your time zone and then click on the arrows below to see more details for each session. 

Singapore
Vienna
New York
San Francisco

IS01 - Satellite CME Symposium Sponsored by Clinical Care Options: Advances in Antibody–Drug Conjugates for Treatment of Non-Small-Cell Lung Cancer
Date: Thursday, January 28, 2021 | Time: 09:15 – 10:15 SGT
Chairs/Speakers: TBD

Agenda
Welcome, Introduction, Polling Questions

Overview & Introduction: Novel Antibody–Drug Conjugates for Treatment of NSCLC
Dr. Ross Camidge, MD, PhD

Activity of ADCs in Clinical Trials for Lung Cancer
Dr. Joel W. Neal, MD, PhD

Panel Discussion and Clinical Pearls: Integrating ADC Therapy in NSCLC
All

Audience Q&A, Panel Discussion

IS02 - Industry Symposium Sponsored by AstraZeneca: Evolving the Role of Immunotherapy in Lung Cancer: ES-SCLC and Unresectable Stage III NSCLC
Date: Thursday, January 28, 2021 | Time: 10:30 - 11:30 SGT
Chairs/Speakers: John Heymach (USA), Masahiro Tsuboi (Japan), Myung-Ju Ahn (S Korea), Glenwood Goss (Canada), Charles Rudin (USA), Suresh Senan (The Netherlands)

Agenda
10:30 SGT Opening Remarks
Masahiro Tsuboi
10:35 SGT Current Strategies for IO Therapy for Unresectable Stage III NSCLC
Glenwood Goss
10:45 SGT Future Strategies: The Potential Role of IO Therapy in Unresectable Stage III NSCLC
Suresh Senan
10:55 SGT Defining the Role of Immunotherapy in the Treatment of ES-SCLC
Myung-Ju Ahn
11:05 SGT Emerging Biomarkers in SCLC
Charles Rudin
11:15 SGT Panel Discussion / Q&A
All

IS03 - Industry Symposium Sponsored by Daiichi Sankyo: Antibody Drug Conjugates (ADC) as Therapeutic Options for Advanced NSCLC: Opportunities and Challenges
Date: Thursday, January 28, 2021 | Time: 11:45 - 12:45 SGT
Chairs/Speakers: Tony Mok (Hong Kong SAR), Pasi Jänne (USA), James Yang (Taiwan)

Agenda
11:45 SGT Welcome and Introduction
Tony Mok
11:50 SGT Evolving challenges for the treatment of advanced NSCLC
Tony Mok
12:00 SGT Emerging ADC targets for the treatment of late-line NSCLC
Pasi Jänne
12:15 SGT ADC therapies as targeted treatment options in patients with advanced NSCLC
James Yang
12:30 SGT Interactive Q+A/Panel Discussion
All

IS04 - Industry Symposium Sponsored by Eli Lilly: Implementing Precision Oncology in the Clinic: Diagnostic Challenges and Best Practices
Date: Thursday, January 28, 2021 | Time: 13:00 - 14:00 SGT
Chairs/Speakers: Koichi Goto (Japan), Herbert Loong (Hong Kong SAR), Fernando López-Ríos (Spain), Giuseppe Curigliano (Italy)

Agenda
13:00 SGT Chair’s Welcome
Koichi Goto
13:04 SGT Introduction to the topic – A brief overview of the 15-year journey of biomarker driven management of NSCLC
Koichi Goto
13:10 SGT Developing best practices for the accurate diagnosis and treatment of all patients with NSCLC
– Practical tips on optimising diagnostic capabilities in the clinic
Herbert Loong
13:22 SGT The roles of the Oncologist and Pathologist in providing an actionable diagnosis
– Discuss the role of the Tumour Board / MDT in implementing precision medicine
Fernando López-Ríos
13:34 SGT Gaining consensus
– An overview of the IASLC, NCCN and ESMO Guidelines for treating and testing patients\
Giuseppe Curigliano
13:44 SGT Panel discussion and Q&A
All
14:00 SGT Symposium close
Koichi Goto

IS05 - Industry Symposium Sponsored by MSD: Redefining Survival Expectations in Lung Cancer
Date: Thursday, January 28, 2021 | Time: 14:15 - 15:15 SGT
Chairs/Speakers: Rina Hui (Australia), Corey Langer (USA), Roy Herbst (USA)

Agenda
14:15 SGT Welcome and Introductions
Rina Hui
14:15 SGT Frontline Immunotherapy Treatment Options in mNSCLC
Rina Hui
14:30 SGT Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Lung Cancer
Roy Herbst
14:45 SGT Choosing Immunotherapy Alone or in Combination in 1L mNSCLC
Corey Langer
15:00 SGT Q&A and Closing Remarks
Rina Hui

IS06 - Industry Symposium Sponsored by Novartis: Novel Frontiers in the treatment of NSCLC
Date: Thursday, January 28, 2021 | Time: 15:30 - 16:30 SGT
Chairs/Speakers: Yi-Long Wu (China), Johan F. Vansteenkiste (Belgium), Yasushi Goto (Japan)

Agenda
15:30 SGT Welcome and introduction
Yi-Long Wu
15:30 SGT Evolution of the NSCLC Treatment Landscape
Yi-Long Wu
15:40 SGT Targeted Therapy for Novel Drivers in NSCLC: Are Expectations Being MET?
Johan F. Vansteenkiste
15:55 SGT Panel discussion
All
15:07 SGT Rethinking Inflammation to Improve Outcomes in NSCLC: IL-1 as an Emerging Target
Yasushi Goto
16:21 SGT Q&A
All
16:29 SGT Closing
Yi-Long Wu

IS07 - Industry Symposium Sponsored by Roche: Expert Perspectives on the Management of Lung Cancer
Date: Thursday, January 28, 2021 | Time: 16:45 - 17:45 SGT
Chairs/Speakers: Ben Solomon (Australia), Shirish Gadgeel (USA), Solange Peters (Switzerland), Ross Soo (Singapore), Martin Rec (Germany)

Agenda
16:45 SGT The Past, Present and Future of Biomarker-driven Advanced NSCLC
Ben Solomon, Shirish Gadgeel, Solange Peters
17:15 SGT Future Directions for Cancer Immunotherapy: Resectable NSCLC and Novel Combinations in Lung Cancer
Ross Soo, Martin Reck, Solange Peters

IS08 - Industry Symposium Sponsored by Janssen: What the Future Holds for Advanced NSCLC Patients with Resistance to EGFR TKIs
Date: Friday, January 29, 2021 | Time: 13:00 – 14:00 SGT
Chairs/Speakers: Tetsuya Mitsudomi (Japan), Byoung Chul Cho (S Korea), Enriqueta Felip (Spain)

Agenda
13:00 SGT Welcome and introductions
Tetsuya Mitsudomi
13:05 SGT A light at the end of the tunnel
Hope for patients with EGFR Exon20 insertion mutations
Byoung Chul Cho
13:25 SGT The dawn of a new era
Novel treatments for patients with TKI resistant disease with common EGFR mutations
Enriqueta Felip
13:45 SGT Live Q&A: From information to transformation
Navigating the evidence with experience sharing in a live forum to improve patient care
All

IS09 - Industry Symposium Sponsored by Pfizer: Expert Question Time: ALK+ NSCLC
Date: Friday, January 29, 2021 | Time: 13:00 – 14:00 SGT
Chairs/Speakers: Seng Weng Wong (Singapore), John Chang (Taiwan), Thanyanan Reungwetwattana (Thailand), Nick Pavlakis (Australia), Nir Peled (Israel)

Agenda
13:00 SGT Welcome and Introduction
Seng Weng Wong
13:05 SGT Navigating Recent Clinical Data for ALK+ TKIs
Thanyanan Reungwetwattana
Selecting Treatment and Management of ALK+ NSCLC
Nick Pavlakis
The Importance of Managing CNS disease
John Chang
The future of ALK+ NSCLC
Nir Peled
13:45 SGT Q&A
All
13:58 SGT Summary, Thank you and Close
Seng Weng Wong

IS10 - Industry Symposium Sponsored by Bristol-Myers Squibb: Thoracic Cancers, New Developments with IO
Date: Friday, January 29, 2021 | Time: 13:00 – 14:00 SGT
Chairs/Speakers: Julie Brahmer (USA), Virginie Westeel (France), Nicolas Girard (France)

Agenda
13:00 SGT Welcome and Introductions
Virginie Westeel, MD, PhD
13:05 SGT What is the role of IO in Non-metastatic NSCLC?
Virginie Westeel, MD, PhD
13:20 SGT IO in the treatment of Metastatic NSCLC, where are we now?
Julie Brahmer, MD, MSc
13:35 SGT Non-Metastatic and Metastatic NSCLC Q&A
Virginie Westeel, MD, PhD
Julie Brahmer, MD, MSc
13:40 SGT What is I-O’s impact on the treatment paradigm for Mesothelioma patients?
Nicolas Girard, MD
13:55 SGT Mesothelioma Q&A and Closing Remarks
Nicolas Girard, MD
Virginie Westeel, MD, PhD

IS11 - Industry Symposium Sponsored by Amgen: Advancing the Next Frontier of Innovation in Lung Cancer Therapies
Date: Saturday, January 30, 2021 | Time: 13:00 – 14:00 SGT
Chairs/Speakers: Stephen Fox (Australia), Koichi Goto (Japan), Julie R. Brahmer (USA)

Agenda
Introductions

Current biomarker landscape in NSCLC
Stephen Fox, MBChB, DPhil

Current unmet need in KRAS G12C-mutated NSCLC
Koichi Goto, MD, PhD

Emerging novel targets for lung cancer
Julie R. Brahmer, MD, MSc

IS12 - Industry Symposium Sponsored by Boehringer Ingelheim: Know Your Patients With NSCLC
Date: Saturday, January 30, 2021 | Time: 13:00 – 14:00 SGT
Chairs/Speakers: David Gandara (USA), John Gosney (UK), Barbara Melosky (Canada), Satoru Miura (Japan)

Agenda
13:00 SGT Introduction
David Gandara, MD
13:05 SGT Know How To Test Your Patients
John Gosney, MD
13:15 SGT Know How To Sequence EGFR TKIs
Barbara Melosky, MD, FRCP(C)
13:25 SGT Know Your Patients With Uncommon EGFR Mutations
Satoru Miura, MD, PhD
13:35 SGT What’s Next For Treatment of Advanced Stage Squamous NSCLC
David Gandara, MD
13:45 SGT Know What’s Next For Your Patients: Looking to the Future
David Gandara, MD
13:55 SGT Closing
David Gandara, MD

IS13 - Satellite CME Symposium Sponsored by ACE Oncology: Hot Topics in the Management of Advanced Non-Small Cell Lung Cancer: Expert Insights on Recent Advances
Date: Saturday, January 30, 2021 | Time: 13:00 – 14:00 SGT
Chairs/Speakers: Daniel S.W. Tan (Singapore), Terufumi Kato (Japan), Herbert Ho Fung Loong (Hong Kong SAR)

Agenda
13:00 SGT Welcome, introduction, and interactive quiz
Daniel S.W. Tan, MD, PhD
13:05 SGT When is the right time to use NGS-based liquid biopsy in advanced NSCLC?
Herbert Ho Fung Loong, MD
13:20 SGT Integrating new targeted therapy for NSCLC with rare oncogenic drivers into clinical practice
Terufumi Kato, MD
13:35 SGT Enhancing immune checkpoint inhibition with bifunctional antibodies
Daniel S.W. Tan, MD, PhD
13:50 SGT Quiz questions revisited and Q&A
All
13:59 SGT Pearls for practice
Daniel S.W. Tan, MD, PhD

IS14 - Industry Symposium Sponsored by AstraZeneca: Evolving Treatment and Testing Paradigms in EGFR-mutated NSCLC: The MDT Perspective
Date: Sunday, January 31, 2021 | Time: 13:00 – 14:00 SGT
Chairs/Speakers: Edward Kim (USA), Alessandro Brunelli (UK), Yoonla Choi (S Korea), Hidehito Horinouchi (Japan), Karen Reckamp (USA)

Agenda
13:00 SGT Welcome and introduction
Edward Kim
13:05 SGT Presentation: Advances and challenges in EGFR-mutated NSCLC
Edward Kim
13:15 SGT Panel discussion: The MDT approach to managing EGFR-mutated NSCLC
Edward Kim (Chair), Alessandro Brunelli, Yoonla Choi, Hidehito Horinouchi, Karen Reckamp
13:45  SGT Audience Q&A
Faculty and audience

IS15 - Industry Symposium Sponsored by Amoy Diagnostics: Lung Cancer Biomarker Panel Testing
Date: Sunday, January 31, 2021 | Time: 13:00 – 14:00 SGT
Chairs/Speakers: Tony Mok (Hong Kong SAR), Koichi Goto (Japan), Caicun Zhou (China)

Agenda
13:00 SGT Opening Remarks
Tony Mok
13:03 SGT Biomarker for Lung Cancer: Right Patient, Right Time, Right Test
Tony Mok
13:21 SGT Biomarker Panel Testing: PCR panel vs NGS panel
Koichi Goto
13:39 SGT Large Scale Real World Study on Rare Actionable Targets in Chinese NSCLC
Caicun Zhou
13:57 SGT Closing Remarks
Tony Mok

IS01 - Satellite CME Symposium Sponsored by Clinical Care Options: Advances in Antibody–Drug Conjugates for Treatment of Non-Small-Cell Lung Cancer
Date: Thursday, January 28, 2021 | Time: 02:15 – 03:15 CET
Chairs/Speakers: TBD

Agenda
Welcome, Introduction, Polling Questions

Overview & Introduction: Novel Antibody–Drug Conjugates for Treatment of NSCLC
Dr. Ross Camidge, MD, PhD

Activity of ADCs in Clinical Trials for Lung Cancer
Dr. Joel W. Neal, MD, PhD

Panel Discussion and Clinical Pearls: Integrating ADC Therapy in NSCLC
All

Audience Q&A, Panel Discussion

IS02 - Industry Symposium Sponsored by AstraZeneca: Evolving the Role of Immunotherapy in Lung Cancer: ES-SCLC and Unresectable Stage III NSCLC
Date: Thursday, January 28, 2021 | Time: 03:30 - 04:30 CET
Chairs/Speakers: John Heymach (USA), Masahiro Tsuboi (Japan), Myung-Ju Ahn (S Korea), Glenwood Goss (Canada), Charles Rudin (USA), Suresh Senan (The Netherlands)

Agenda
03:30 CET Opening Remarks
Masahiro Tsuboi
03:35 CET Current Strategies for IO Therapy for Unresectable Stage III NSCLC
Glenwood Goss
03:45 CET Future Strategies: The Potential Role of IO Therapy in Unresectable Stage III NSCLC
Suresh Senan
03:55 CET Defining the Role of Immunotherapy in the Treatment of ES-SCLC
Myung-Ju Ahn
04:05 CET Emerging Biomarkers in SCLC
Charles Rudin
04:15 CET Panel Discussion / Q&A
All

IS03 - Industry Symposium Sponsored by Daiichi Sankyo: Antibody Drug Conjugates (ADC) as Therapeutic Options for Advanced NSCLC: Opportunities and Challenges
Date: Thursday, January 28, 2021 | Time: 04:45 - 05:45 CET
Chairs/Speakers: Tony Mok (Hong Kong SAR), Pasi Jänne (USA), James Yang (Taiwan)

Agenda
04:45 CET Welcome and Introduction
Tony Mok
04:50 CET Evolving challenges for the treatment of advanced NSCLC
Tony Mok
05:00 CET Emerging ADC targets for the treatment of late-line NSCLC
Pasi Jänne
05:15 CET ADC therapies as targeted treatment options in patients with advanced NSCLC
James Yang
05:30 CET Interactive Q+A/Panel Discussion
All

IS04 - Industry Symposium Sponsored by Eli Lilly: Implementing Precision Oncology in the Clinic: Diagnostic Challenges and Best Practices
Date: Thursday, January 28, 2021 | Time: 06:00 - 07:00 CET
Chairs/Speakers: Koichi Goto (Japan), Herbert Loong (Hong Kong SAR), Fernando López-Ríos (Spain), Giuseppe Curigliano (Italy)

Agenda
06:00 CET Chair’s Welcome
Koichi Goto
06:04 CET Introduction to the topic – A brief overview of the 15-year journey of biomarker driven management of NSCLC
Koichi Goto
06:10 CET Developing best practices for the accurate diagnosis and treatment of all patients with NSCLC
– Practical tips on optimising diagnostic capabilities in the clinic
Herbert Loong
06:22 CET The roles of the Oncologist and Pathologist in providing an actionable diagnosis
– Discuss the role of the Tumour Board / MDT in implementing precision medicine
Fernando López-Ríos
06:34 CET Gaining consensus
– An overview of the IASLC, NCCN and ESMO Guidelines for treating and testing patients\
Giuseppe Curigliano
06:44 CET Panel discussion and Q&A
All
07:00 CET Symposium close
Koichi Goto

IS05 - Industry Symposium Sponsored by MSD: Redefining Survival Expectations in Lung Cancer
Date: Thursday, January 28, 2021 | Time: 07:15 - 08:15 CET
Chairs/Speakers: Rina Hui (Australia), Corey Langer (USA), Roy Herbst (USA)

Agenda
07:15 CET Welcome and Introductions
Rina Hui
07:15 CET Frontline Immunotherapy Treatment Options in mNSCLC
Rina Hui
07:30 CET Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Lung Cancer
Roy Herbst
07:45 CET Choosing Immunotherapy Alone or in Combination in 1L mNSCLC
Corey Langer
08:00 CET Q&A and Closing Remarks
Rina Hui

IS06 - Industry Symposium Sponsored by Novartis: Novel Frontiers in the Treatment of NSCLC
Date: Thursday, January 28, 2021 | Time: 08:30 - 09:30 CET
Chairs/Speakers: Yi-Long Wu (China), Johan F. Vansteenkiste (Belgium), Yasushi Goto (Japan)

Agenda
08:30 CET Welcome and introduction
Yi-Long Wu
08:30 CET Evolution of the NSCLC Treatment Landscape
Yi-Long Wu
08:40 CET Targeted Therapy for Novel Drivers in NSCLC: Are Expectations Being MET?
Johan F. Vansteenkiste
08:55 CET Panel discussion
All
09:07 CET Rethinking Inflammation to Improve Outcomes in NSCLC: IL-1 as an Emerging Target
Yasushi Goto
09:21 CET Q&A
All
09:29 CET Closing
Yi-Long Wu

IS07 - Industry Symposium Sponsored by Roche: Expert Perspectives on the Management of Lung Cancer
Date: Thursday, January 28, 2021 | Time: 09:45 - 10:45 CET
Chairs/Speakers: Ben Solomon (Australia), Shirish Gadgeel (USA), Solange Peters (Switzerland), Ross Soo (Singapore), Martin Rec (Germany)

Agenda
09:45 CET The Past, Present and Future of Biomarker-driven Advanced NSCLC
Ben Solomon, Shirish Gadgeel, Solange Peters
10:15 CET Future Directions for Cancer Immunotherapy: Resectable NSCLC and Novel Combinations in Lung Cancer
Ross Soo, Martin Reck, Solange Peters

IS08 - Industry Symposium Sponsored by Janssen: What the Future Holds for Advanced NSCLC Patients with Resistance to EGFR TKIs
Date: Friday, January 29, 2021 | Time: 06:00 - 07:00 CET
Chairs/Speakers: Tetsuya Mitsudomi (Japan), Byoung Chul Cho (S Korea), Enriqueta Felip (Spain)

Agenda
06:00 CET Welcome and introductions
Tetsuya Mitsudomi
06:05 CET A light at the end of the tunnel
Hope for patients with EGFR Exon20 insertion mutations
Byoung Chul Cho
06:25 CET The dawn of a new era
Novel treatments for patients with TKI resistant disease with common EGFR mutations
Enriqueta Felip
06:45 CET Live Q&A: From information to transformation
Navigating the evidence with experience sharing in a live forum to improve patient care
All

IS09 - Industry Symposium Sponsored by Pfizer: Expert Question Time: ALK+ NSCLC
Date: Friday, January 29, 2021 | Time: 06:00 - 07:00 CET
Chairs/Speakers: Seng Weng Wong (Singapore), John Chang (Taiwan), Thanyanan Reungwetwattana (Thailand), Nick Pavlakis (Australia), Nir Peled (Israel)

Agenda
06:00 CET Welcome and Introduction
Seng Weng Wong
06:05 CET Navigating Recent Clinical Data for ALK+ TKIs
Thanyanan ReungwetwattanaSelecting Treatment and Management of ALK+ NSCLC
Nick Pavlakis

The Importance of Managing CNS disease
John Chang

The future of ALK+ NSCLC
Nir Peled

06:45 CET Q&A
All
06:58 CET Summary, Thank you and Close
Seng Weng Wong

IS10 - Industry Symposium Sponsored by Bristol-Myers Squibb: Thoracic Cancers, New Developments with IO
Date: Friday, January 29, 2021 | Time: 06:00 - 07:00 CET
Chairs/Speakers: Julie Brahmer (USA), Virginie Westeel (France), Nicolas Girard (France)

Agenda
06:00 CET Welcome and Introductions
Virginie Westeel, MD, PhD
06:05 CET What is the role of IO in Non-metastatic NSCLC?
Virginie Westeel, MD, PhD
06:20 CET IO in the treatment of Metastatic NSCLC, where are we now?
Julie Brahmer, MD, MSc
06:35 CET Non-Metastatic and Metastatic NSCLC Q&A
Virginie Westeel, MD, PhD
Julie Brahmer, MD, MSc
06:40 CET What is I-O’s impact on the treatment paradigm for Mesothelioma patients?
Nicolas Girard, MD
06:55 CET Mesothelioma Q&A and Closing Remarks
Nicolas Girard, MD
Virginie Westeel, MD, PhD

IS11 - Industry Symposium Sponsored by Amgen: Advancing the Next Frontier of Innovation in Lung Cancer Therapies
Date: Saturday, January 30, 2021 | Time: 06:00 - 07:00 CET
Chairs/Speakers: Stephen Fox (Australia), Koichi Goto (Japan), Julie R. Brahmer (USA)

Agenda
Introductions

Current biomarker landscape in NSCLC
Stephen Fox, MBChB, DPhil

Current unmet need in KRAS G12C-mutated NSCLC
Koichi Goto, MD, PhD

Emerging novel targets for lung cancer
Julie R. Brahmer, MD, MSc

IS12 - Industry Symposium Sponsored by Boehringer Ingelheim: Know Your Patients With NSCLC
Date: Saturday, January 30, 2021 | Time: 06:00 - 07:00 CET
Chairs/Speakers: David Gandara (USA), John Gosney (UK), Barbara Melosky (Canada), Satoru Miura (Japan)

Agenda
06:00 CET Introduction
David Gandara, MD
06:05 CET Know How To Test Your Patients
John Gosney, MD
06:15 CET Know How To Sequence EGFR TKIs
Barbara Melosky, MD, FRCP(C)
06:25 CET Know Your Patients With Uncommon EGFR Mutations
Satoru Miura, MD, PhD
06:35 CET What’s Next For Treatment of Advanced Stage Squamous NSCLC
David Gandara, MD
06:45 CET Know What’s Next For Your Patients: Looking to the Future
David Gandara, MD
06:55 CET Closing
David Gandara, MD

IS13 - Satellite CME Symposium Sponsored by ACE Oncology: Hot Topics in the Management of Advanced Non-Small Cell Lung Cancer: Expert Insights on Recent Advances
Date: Saturday, January 30, 2021 | Time: 06:00 - 07:00 CET
Chairs/Speakers: Daniel S.W. Tan (Singapore), Terufumi Kato (Japan), Herbert Ho Fung Loong (Hong Kong SAR)

Agenda
06:00 CET Welcome, introduction, and interactive quiz
Daniel S.W. Tan, MD, PhD
06:05 CET When is the right time to use NGS-based liquid biopsy in advanced NSCLC?
Herbert Ho Fung Loong, MD
06:20 CET Integrating new targeted therapy for NSCLC with rare oncogenic drivers into clinical practice
Terufumi Kato, MD
06:35 CET Enhancing immune checkpoint inhibition with bifunctional antibodies
Daniel S.W. Tan, MD, PhD
06:50 CET Quiz questions revisited and Q&A
All
06:59 CET Pearls for practice
Daniel S.W. Tan, MD, PhD

IS14 - Industry Symposium Sponsored by AstraZeneca: Evolving Treatment and Testing Paradigms in EGFR-mutated NSCLC: The MDT Perspective
Date: Sunday, January 31, 2021 | Time: 06:00 - 07:00 CET
Chairs/Speakers: Edward Kim (USA), Alessandro Brunelli (UK), Yoonla Choi (S Korea), Hidehito Horinouchi (Japan), Karen Reckamp (USA)

Agenda
06:00 CET Welcome and introduction
Edward Kim
06:05 CET Presentation: Advances and challenges in EGFR-mutated NSCLC
Edward Kim
06:15 CET Panel discussion: The MDT approach to managing EGFR-mutated NSCLC
Edward Kim (Chair), Alessandro Brunelli, Yoonla Choi, Hidehito Horinouchi, Karen Reckamp
06:45 CET Audience Q&A
Faculty and audience

IS15 - Industry Symposium Sponsored by Amoy Diagnostics: Lung Cancer Biomarker Panel Testing

Date: Sunday, January 31, 2021 | Time: 06:00 - 07:00 CET

Chairs/Speakers: Tony Mok (Hong Kong SAR), Koichi Goto (Japan), Caicun Zhou (China

Agenda
06:00 CET Opening Remarks
Tony Mok
06:03 CET Biomarker for Lung Cancer: Right Patient, Right Time, Right Test
Tony Mok
06:21 CET Biomarker Panel Testing: PCR panel vs NGS panel
Koichi Goto
06:39 CET Large Scale Real World Study on Rare Actionable Targets in Chinese NSCLC
Caicun Zhou
06:57 CET Closing Remarks
Tony Mok

IS01 - Satellite CME Symposium Sponsored by Clinical Care Options: Advances in Antibody–Drug Conjugates for Treatment of Non-Small-Cell Lung Cancer
Date: Wednesday, January 27, 2021 | Time: 20:15 - 21:15 EST
Chairs/Speakers: TBD

Agenda
Welcome, Introduction, Polling Questions

Overview & Introduction: Novel Antibody–Drug Conjugates for Treatment of NSCLC
Dr. Ross Camidge, MD, PhD

Activity of ADCs in Clinical Trials for Lung Cancer
Dr. Joel W. Neal, MD, PhD

Panel Discussion and Clinical Pearls: Integrating ADC Therapy in NSCLC
All

Audience Q&A, Panel Discussion

IS02 - Industry Symposium Sponsored by AstraZeneca: Evolving the Role of Immunotherapy in Lung Cancer: ES-SCLC and Unresectable Stage III NSCLC
Date: Wednesday, January 27, 2021 | Time: 21:30 - 22:30 EST
Chairs/Speakers: John Heymach (USA), Masahiro Tsuboi (Japan), Myung-Ju Ahn (S Korea), Glenwood Goss (Canada), Charles Rudin (USA), Suresh Senan (The Netherlands)

Agenda
21:30 EST Opening Remarks
Masahiro Tsuboi
21:35 EST Current Strategies for IO Therapy for Unresectable Stage III NSCLC
Glenwood Goss
21:45 EST Future Strategies: The Potential Role of IO Therapy in Unresectable Stage III NSCLC
Suresh Senan
21:55 EST Defining the Role of Immunotherapy in the Treatment of ES-SCLC
Myung-Ju Ahn
22:05 EST Emerging Biomarkers in SCLC
Charles Rudin
22:15 EST Panel Discussion / Q&A
All

IS03 - Industry Symposium Sponsored by Daiichi Sankyo: Antibody Drug Conjugates (ADC) as Therapeutic Options for Advanced NSCLC: Opportunities and Challenges
Date: Wednesday, January 27, 2021 | Time: 22:45 - 23:45 EST
Chairs/Speakers: Tony Mok (Hong Kong SAR), Pasi Jänne (USA), James Yang (Taiwan)

Agenda
22:45 EST Welcome and Introduction
Tony Mok
22:50 EST Evolving challenges for the treatment of advanced NSCLC
Tony Mok
23:00 EST Emerging ADC targets for the treatment of late-line NSCLC
Pasi Jänne
23:15 EST ADC therapies as targeted treatment options in patients with advanced NSCLC
James Yang
23:30 EST Interactive Q+A/Panel Discussion
All

IS04 - Industry Symposium Sponsored by Eli Lilly: Implementing Precision Oncology in the Clinic: Diagnostic Challenges and Best Practices
Date: Thursday, January 28 2021 | Time: 00:00 - 01:00 EST
Chairs/Speakers: Koichi Goto (Japan), Herbert Loong (Hong Kong SAR), Fernando López-Ríos (Spain), Giuseppe Curigliano (Italy)

Agenda
00:00 EST Chair’s Welcome
Koichi Goto
00:04 EST Introduction to the topic – A brief overview of the 15-year journey of biomarker driven management of NSCLC
Koichi Goto
00:10 EST Developing best practices for the accurate diagnosis and treatment of all patients with NSCLC
– Practical tips on optimising diagnostic capabilities in the clinic
Herbert Loong
00:22 EST The roles of the Oncologist and Pathologist in providing an actionable diagnosis
– Discuss the role of the Tumour Board / MDT in implementing precision medicine
Fernando López-Ríos
00:34 EST Gaining consensus
– An overview of the IASLC, NCCN and ESMO Guidelines for treating and testing patients\
Giuseppe Curigliano
00:44 EST Panel discussion and Q&A
All
01:00 EST Symposium close
Koichi Goto

IS05 - Industry Symposium Sponsored by MSD: Redefining Survival Expectations in Lung Cancer
Date: Thursday, January 28 2021 | Time: 01:15 - 02:15 EST
Chairs/Speakers: Rina Hui (Australia), Corey Langer (USA), Roy Herbst (USA)

Agenda
01:15 EST Welcome and Introductions
Rina Hui
01:15 EST Frontline Immunotherapy Treatment Options in mNSCLC
Rina Hui
01:30 EST Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Lung Cancer
Roy Herbst
01:45 EST Choosing Immunotherapy Alone or in Combination in 1L mNSCLC
Corey Langer
02:00 EST Q&A and Closing Remarks
Rina Hui

IS06 - Industry Symposium Sponsored by Novartis: Novel Frontiers in the Treatment of NSCLC
Date: Thursday, January 28 2021 | Time: 02:30 - 03:30 EST
Chairs/Speakers: Yi-Long Wu (China), Johan F. Vansteenkiste (Belgium), Yasushi Goto (Japan)

Agenda
02:30 PST Welcome and introduction
Yi-Long Wu
02:30 EST Evolution of the NSCLC Treatment Landscape
Yi-Long Wu
02:40 EST Targeted Therapy for Novel Drivers in NSCLC: Are Expectations Being MET?
Johan F. Vansteenkiste
02:55 EST Panel discussion
All
03:07 EST Rethinking Inflammation to Improve Outcomes in NSCLC: IL-1 as an Emerging Target
Yasushi Goto
03:21 EST Q&A
All
03:29 EST Closing
Yi-Long Wu

IS07 - Industry Symposium Sponsored by Roche: Expert Perspectives on the Management of Lung Cancer
Date: Thursday, January 28 2021 | Time: 03:45 - 04:45 EST
Chairs/Speakers: Ben Solomon (Australia), Shirish Gadgeel (USA), Solange Peters (Switzerland), Ross Soo (Singapore), Martin Rec (Germany)

Agenda
03:45 EST The Past, Present and Future of Biomarker-driven Advanced NSCLC
Ben Solomon, Shirish Gadgeel, Solange Peters
04:15 EST Future Directions for Cancer Immunotherapy: Resectable NSCLC and Novel Combinations in Lung Cancer
Ross Soo, Martin Reck, Solange Peters

IS08 - Industry Symposium Sponsored by Janssen: What the Future Holds for Advanced NSCLC Patients with Resistance to EGFR TKIs
Date: Friday, January 29, 2021 | Time: 00:00 - 01:00 EST
Chairs/Speakers: Tetsuya Mitsudomi (Japan), Byoung Chul Cho (S Korea), Enriqueta Felip (Spain)

Agenda
00:00 EST Welcome and introductions
Tetsuya Mitsudomi
00:05 EST A light at the end of the tunnel
Hope for patients with EGFR Exon20 insertion mutations
Byoung Chul Cho
00:25 EST The dawn of a new era
Novel treatments for patients with TKI resistant disease with common EGFR mutations
Enriqueta Felip
00:45 EST Live Q&A: From information to transformation
Navigating the evidence with experience sharing in a live forum to improve patient care
All

IS09 - Industry Symposium Sponsored by Pfizer: Expert Question Time: ALK+ NSCLC
Date: Friday, January 29, 2021 | Time: 00:00 - 01:00 EST
Chairs/Speakers: Seng Weng Wong (Singapore), John Chang (Taiwan), Thanyanan Reungwetwattana (Thailand), Nick Pavlakis (Australia), Nir Peled (Israel)

Agenda
00:00 EST Welcome and Introduction
Seng Weng Wong
00:05 EST Navigating Recent Clinical Data for ALK+ TKIs
Thanyanan Reungwetwattana

Selecting Treatment and Management of ALK+ NSCLC
Nick Pavlakis

The Importance of Managing CNS disease
John Chang

The future of ALK+ NSCLC
Nir Peled

00:45 EST Q&A
All
00:58 EST Summary, Thank you and Close
Seng Weng Wong

IS10 - Industry Symposium Sponsored by Bristol-Myers Squibb: Thoracic Cancers, New Developments with IO
Date: Friday, January 29, 2021 | Time: 00:00 - 01:00 EST
Chairs/Speakers: Julie Brahmer (USA), Virginie Westeel (France), Nicolas Girard (France)

Agenda
00:00 EST Welcome and Introductions
Virginie Westeel, MD, PhD
00:05 EST What is the role of IO in Non-metastatic NSCLC?
Virginie Westeel, MD, PhD
00:20 EST IO in the treatment of Metastatic NSCLC, where are we now?
Julie Brahmer, MD, MSc
00:35 EST Non-Metastatic and Metastatic NSCLC Q&A
Virginie Westeel, MD, PhD
Julie Brahmer, MD, MSc
00:40 EST What is I-O’s impact on the treatment paradigm for Mesothelioma patients?
Nicolas Girard, MD
00:55 EST Mesothelioma Q&A and Closing Remarks
Nicolas Girard, MD
Virginie Westeel, MD, PhD

IS11 - Industry Symposium Sponsored by Amgen: Advancing the Next Frontier of Innovation in Lung Cancer Therapies
Date: Saturday, January 20, 2021 | Time: 00:00 - 01:00 EST
Chairs/Speakers: Stephen Fox (Australia), Koichi Goto (Japan), Julie R. Brahmer (USA)

Agenda
Introductions

Current biomarker landscape in NSCLC
Stephen Fox, MBChB, DPhil

Current unmet need in KRAS G12C-mutated NSCLC
Koichi Goto, MD, PhD

Emerging novel targets for lung cancer
Julie R. Brahmer, MD, MSc

IS12 - Industry Symposium Sponsored by Boehringer Ingelheim: Know Your Patients With NSCLC
Date: Saturday, January 20, 2021 | Time: 00:00 - 01:00 EST
Chairs/Speakers: David Gandara (USA), John Gosney (UK), Barbara Melosky (Canada), Satoru Miura (Japan)

Agenda
00:00 EST Introduction
David Gandara, MD
00:05 EST Know How To Test Your Patients
John Gosney, MD
00:15 EST Know How To Sequence EGFR TKIs
Barbara Melosky, MD, FRCP(C)
00:25 EST Know Your Patients With Uncommon EGFR Mutations
Satoru Miura, MD, PhD
00:35 EST What’s Next For Treatment of Advanced Stage Squamous NSCLC
David Gandara, MD
00:45 EST Know What’s Next For Your Patients: Looking to the Future
David Gandara, MD
00:55 EST Closing
David Gandara, MD

IS13 - Satellite CME Symposium Sponsored by ACE Oncology: Hot Topics in the Management of Advanced Non-Small Cell Lung Cancer: Expert Insights on Recent Advances
Date: Sunday, January 31, 2021 | Time: 00:00 - 01:00 EST
Chairs/Speakers: Daniel S.W. Tan (Singapore), Terufumi Kato (Japan), Herbert Ho Fung Loong (Hong Kong SAR)

Agenda
00:00 EST Welcome, introduction, and interactive quiz
Daniel S.W. Tan, MD, PhD
00:05 EST When is the right time to use NGS-based liquid biopsy in advanced NSCLC?
Herbert Ho Fung Loong, MD
00:20 EST Integrating new targeted therapy for NSCLC with rare oncogenic drivers into clinical practice
Terufumi Kato, MD
00:35 EST Enhancing immune checkpoint inhibition with bifunctional antibodies
Daniel S.W. Tan, MD, PhD
00:50 EST Quiz questions revisited and Q&A
All
00:59 EST Pearls for practice
Daniel S.W. Tan, MD, PhD

IS14 - Industry Symposium Sponsored by AstraZeneca: Evolving Treatment and Testing Paradigms in EGFR-mutated NSCLC: The MDT Perspective
Date: Sunday, January 31, 2021 | Time: 00:00 - 01:00 EST
Chairs/Speakers: Edward Kim (USA), Alessandro Brunelli (UK), Yoonla Choi (S Korea), Hidehito Horinouchi (Japan), Karen Reckamp (USA)

Agenda
00:00 EST Welcome and introduction
Edward Kim
00:05 EST Presentation: Advances and challenges in EGFR-mutated NSCLC
Edward Kim
00:15 EST Panel discussion: The MDT approach to managing EGFR-mutated NSCLC
Edward Kim (Chair), Alessandro Brunelli, Yoonla Choi, Hidehito Horinouchi, Karen Reckamp
00:45 EST Audience Q&A
Faculty and audience

IS15 - Industry Symposium Sponsored by Amoy Diagnostics: Lung Cancer Biomarker Panel Testing

Date: Sunday, January 31, 2021 | Time: 00:00 - 01:00 EST

Chairs/Speakers: Tony Mok (Hong Kong SAR), Koichi Goto (Japan), Caicun Zhou (China)

Agenda
00:00 EST Opening Remarks
Tony Mok
00:03 EST Biomarker for Lung Cancer: Right Patient, Right Time, Right Test
Tony Mok
00:21 EST Biomarker Panel Testing: PCR panel vs NGS panel
Koichi Goto
00:39 EST Large Scale Real World Study on Rare aActionable Targets in Chinese NSCLC
Caicun Zhou
00:57 EST Closing Remarks
Tony Mok

IS01 - Satellite CME Symposium Sponsored by Clinical Care Options: Advances in Antibody–Drug Conjugates for Treatment of Non-Small-Cell Lung Cancer
Date: Wednesday, January 27, 2021 | Time: 17:15 - 18:15 PST
Chairs/Speakers: TBD

Agenda
Welcome, Introduction, Polling Questions

Overview & Introduction: Novel Antibody–Drug Conjugates for Treatment of NSCLC
Dr. Ross Camidge, MD, PhD

Activity of ADCs in Clinical Trials for Lung Cancer
Dr. Joel W. Neal, MD, PhD

Panel Discussion and Clinical Pearls: Integrating ADC Therapy in NSCLC
All

Audience Q&A, Panel Discussion

IS02 - Industry Symposium Sponsored by AstraZeneca: Evolving the Role of Immunotherapy in Lung Cancer: ES-SCLC and Unresectable Stage III NSCLC
Date: Wednesday, January 27, 2021 | Time: 18:30 - 19:30 PST
Chairs/Speakers: John Heymach (USA), Masahiro Tsuboi (Japan), Myung-Ju Ahn (S Korea), Glenwood Goss (Canada), Charles Rudin (USA), Suresh Senan (The Netherlands)

Agenda
18:30 PST Opening Remarks
Masahiro Tsuboi
18:35 PST Current Strategies for IO Therapy for Unresectable Stage III NSCLC
Glenwood Goss
18:45 PST Future Strategies: The Potential Role of IO Therapy in Unresectable Stage III NSCLC
Suresh Senan
18:55 PST Defining the Role of Immunotherapy in the Treatment of ES-SCLC
Myung-Ju Ahn
19:05 PST Emerging Biomarkers in SCLC
Charles Rudin
19:15 PST Panel Discussion / Q&A
All

IS03 - Industry Symposium Sponsored by Daiichi Sankyo: Antibody Drug Conjugates (ADC) as Therapeutic Options for Advanced NSCLC: Opportunities and Challenges
Date: Wednesday, January 27, 2021 | Time: 19:45 - 20:45 PST
Chairs/Speakers: Tony Mok (Hong Kong SAR), Pasi Jänne (USA), James Yang (Taiwan)

Agenda
19:45 PST Welcome and Introduction
Tony Mok
19:50 PST Evolving challenges for the treatment of advanced NSCLC
Tony Mok
20:00 PST Emerging ADC targets for the treatment of late-line NSCLC
Pasi Jänne
20:15 PST ADC therapies as targeted treatment options in patients with advanced NSCLC
James Yang
20:30 PST Interactive Q+A/Panel Discussion
All

IS04 - Industry Symposium Sponsored by Eli Lilly: Implementing Precision Oncology in the Clinic: Diagnostic Challenges and Best Practices
Date: Wednesday, January 27, 2021 | Time: 21:00 - 22:00 PST
Chairs/Speakers: Koichi Goto (Japan), Herbert Loong (Hong Kong SAR), Fernando López-Ríos (Spain), Giuseppe Curigliano (Italy)

Agenda
21:00 PST Chair’s Welcome
Koichi Goto
21:04 PST Introduction to the topic – A brief overview of the 15-year journey of biomarker driven management of NSCLC
Koichi Goto
21:10 PST Developing best practices for the accurate diagnosis and treatment of all patients with NSCLC
– Practical tips on optimising diagnostic capabilities in the clinic
Herbert Loong
21:22 PST The roles of the Oncologist and Pathologist in providing an actionable diagnosis
– Discuss the role of the Tumour Board / MDT in implementing precision medicine
Fernando López-Ríos
21:34 PST Gaining consensus
– An overview of the IASLC, NCCN and ESMO Guidelines for treating and testing patients\
Giuseppe Curigliano
21:44 PST Panel discussion and Q&A
All
22:00 PST Symposium close
Koichi Goto

IS05 - Industry Symposium Sponsored by MSD: Redefining Survival Expectations in Lung Cancer
Date: Wednesday, January 27, 2021 | Time: 22:15 - 23:15 PST
Chairs/Speakers: Rina Hui (Australia), Corey Langer (USA), Roy Herbst (USA)

Agenda
22:15 PST Welcome and Introductions
Rina Hui
22:15 PST Frontline Immunotherapy Treatment Options in mNSCLC
Rina Hui
22:30 PST Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Lung Cancer
Roy Herbst
22:45 PST Choosing Immunotherapy Alone or in Combination in 1L mNSCLC
Corey Langer
23:00 PST Q&A and Closing Remarks
Rina Hui

IS06 - Industry Symposium Sponsored by Novartis: Novel Frontiers in the treatment of NSCLC
Date: Wednesday, January 27, 2021 | Time: 23:30 - 00:30 PST
Chairs/Speakers: Yi-Long Wu (China), Johan F. Vansteenkiste (Belgium), Yasushi Goto (Japan)

Agenda
23:30 PST Welcome and introduction
Yi-Long Wu
23:30 PST Evolution of the NSCLC Treatment Landscape
Yi-Long Wu
23:40 PST Targeted Therapy for Novel Drivers in NSCLC: Are Expectations Being MET?
Johan F. Vansteenkiste
23:55 PST Panel discussion
All
00:07 PST Rethinking Inflammation to Improve Outcomes in NSCLC: IL-1 as an Emerging Target
Yasushi Goto
00:21 PST Q&A
All
00:29 PST Closing
Yi-Long Wu

IS07 - Industry Symposium Sponsored by Roche: Expert Perspectives on the Management of Lung Cancer
Date: Thursday, January 28, 2021 | Time: 00:45 - 01:45 PST
Chairs/Speakers: Ben Solomon (Australia), Shirish Gadgeel (USA), Solange Peters (Switzerland), Ross Soo (Singapore), Martin Rec (Germany)

Agenda
00:45 PST The Past, Present and Future of Biomarker-driven Advanced NSCLC
Ben Solomon, Shirish Gadgeel, Solange Peters
01:15 PST Future Directions for Cancer Immunotherapy: Resectable NSCLC and Novel Combinations in Lung Cancer
Ross Soo, Martin Reck, Solange Peters

IS08 - Industry Symposium Sponsored by Janssen: What the Future Holds for Advanced NSCLC Patients with Resistance to EGFR TKIs
Date: Thursday, January 28, 2021 | Time: 21:00 - 22:00 PST
Chairs/Speakers: Tetsuya Mitsudomi (Japan), Byoung Chul Cho (S Korea), Enriqueta Felip (Spain)

Agenda
21:00 PST Welcome and introductions
Tetsuya Mitsudomi
21:05 PST A light at the end of the tunnel
Hope for patients with EGFR Exon20 insertion mutations
Byoung Chul Cho
21:25 PST The dawn of a new era
Novel treatments for patients with TKI resistant disease with common EGFR mutations
Enriqueta Felip
21:45 PST Live Q&A: From information to transformation
Navigating the evidence with experience sharing in a live forum to improve patient care
All

IS09 - Industry Symposium Sponsored by Pfizer: Expert Question Time: ALK+ NSCLC
Date: Thursday, January 28, 2021 | Time: 21:00 - 22:00 PST
Chairs/Speakers: Seng Weng Wong (Singapore), John Chang (Taiwan), Thanyanan Reungwetwattana (Thailand), Nick Pavlakis (Australia), Nir Peled (Israel)

Agenda
21:00 PST Welcome and Introduction
Seng Weng Wong
21:05 PST Navigating Recent Clinical Data for ALK+ TKIs
Thanyanan ReungwetwattanaSelecting Treatment and Management of ALK+ NSCLC
Nick Pavlakis

The Importance of Managing CNS disease
John Chang

The future of ALK+ NSCLC
Nir Peled

21:45 PST Q&A
All
21:58 PST Summary, Thank you and Close
Seng Weng Wong

IS10 - Industry Symposium Sponsored by Bristol-Myers Squibb: Thoracic Cancers, New Developments with IO
Date: Thursday, January 28, 2021 | Time: 21:00 - 22:00 PST
Chairs/Speakers: Julie Brahmer (USA), Virginie Westeel (France), Nicolas Girard (France)

Agenda
21:00 PST Welcome and Introductions
Virginie Westeel, MD, PhD
21:05 PST What is the role of IO in Non-metastatic NSCLC?
Virginie Westeel, MD, PhD
21:20 PST IO in the treatment of Metastatic NSCLC, where are we now?
Julie Brahmer, MD, MSc
21:35 PST Non-Metastatic and Metastatic NSCLC Q&A
Virginie Westeel, MD, PhD
Julie Brahmer, MD, MSc
21:40 PST What is I-O’s impact on the treatment paradigm for Mesothelioma patients?
Nicolas Girard, MD
21:55 PST Mesothelioma Q&A and Closing Remarks
Nicolas Girard, MD
Virginie Westeel, MD, PhD

IS11 - Industry Symposium Sponsored by Amgen: Advancing the Next Frontier of Innovation in Lung Cancer Therapies
Date: Friday, January 29, 2021 | Time: 21:00 - 22:00 PST
Chairs/Speakers: Stephen Fox (Australia), Koichi Goto (Japan), Julie R. Brahmer (USA)

Agenda
Introductions

Current biomarker landscape in NSCLC
Stephen Fox, MBChB, DPhil

Current unmet need in KRAS G12C-mutated NSCLC
Koichi Goto, MD, PhD

Emerging novel targets for lung cancer
Julie R. Brahmer, MD, MSc

IS12 - Industry Symposium Sponsored by Boehringer Ingelheim: Know Your Patients With NSCLC
Date: Friday, January 29, 2021 | Time: 21:00 - 22:00 PST
Chairs/Speakers: David Gandara (USA), John Gosney (UK), Barbara Melosky (Canada), Satoru Miura (Japan)

Agenda
21:00 PST Introduction
David Gandara, MD
21:05 PST Know How To Test Your Patients
John Gosney, MD
21:15 PST Know How To Sequence EGFR TKIs
Barbara Melosky, MD, FRCP(C)
21:25 PST Know Your Patients With Uncommon EGFR Mutations
Satoru Miura, MD, PhD
21:35 PST What’s Next For Treatment of Advanced Stage Squamous NSCLC
David Gandara, MD
21:45 PST Know What’s Next For Your Patients: Looking to the Future
David Gandara, MD
21:55 PST Closing
David Gandara, MD

IS13 - Satellite CME Symposium Sponsored by ACE Oncology: Hot Topics in the Management of Advanced Non-Small Cell Lung Cancer: Expert Insights on Recent Advances
Date: Saturday, January 30, 2021 | Time: 21:00 - 22:00 PST
Chairs/Speakers: Daniel S.W. Tan (Singapore), Terufumi Kato (Japan), Herbert Ho Fung Loong (Hong Kong SAR)

Agenda
21:00 PST Welcome, introduction, and interactive quiz
Daniel S.W. Tan, MD, PhD
21:05 PST When is the right time to use NGS-based liquid biopsy in advanced NSCLC?
Herbert Ho Fung Loong, MD
21:20 PST Integrating new targeted therapy for NSCLC with rare oncogenic drivers into clinical practice
Terufumi Kato, MD
21:35 PST Enhancing immune checkpoint inhibition with bifunctional antibodies
Daniel S.W. Tan, MD, PhD
21:50 PST Quiz questions revisited and Q&A
All
21:59 PST Pearls for practice
Daniel S.W. Tan, MD, PhD

IS14 - Industry Symposium Sponsored by AstraZeneca: Evolving Treatment and Testing Paradigms in EGFR-mutated NSCLC: The MDT Perspective
Date: Saturday, January 30, 2021 | Time: 21:00 - 22:00 PST
Chairs/Speakers: Edward Kim (USA), Alessandro Brunelli (UK), Yoonla Choi (S Korea), Hidehito Horinouchi (Japan), Karen Reckamp (USA)

Agenda
21:00 PST Welcome and introduction
Edward Kim
21:05 PST Presentation: Advances and challenges in EGFR-mutated NSCLC
Edward Kim
21:15 PST Panel discussion: The MDT approach to managing EGFR-mutated NSCLC
Edward Kim (Chair), Alessandro Brunelli, Yoonla Choi, Hidehito Horinouchi, Karen Reckamp
21:45 PST Audience Q&A
Faculty and audience

IS15 - Industry Symposium Sponsored by Amoy Diagnostics: Lung Cancer Biomarker Panel Testing

Date: Saturday, January 30, 2021 | Time: 21:00 - 22:00 PST

Chairs/Speakers: Tony Mok (Hong Kong SAR), Koichi Goto (Japan), Caicun Zhou (China)

Agenda
21:00 PST Opening Remarks
Tony Mok
21:03 PST Biomarker for Lung Cancer: Right Patient, Right Time, Right Test
Tony Mok
21:21 PST Biomarker Panel Testing: PCR panel vs NGS panel
Koichi Goto
21:39 PST Large Scale Real World Study on Rare Actionable Targets in Chinese NSCLC
Caicun Zhou
21:57 PST Closing Remarks
Tony Mok

Contact

Should you have any questions regarding the Industry & Satellite CME Symposia, please contact wclc2020-industry at icsevents.com.

Industry Symposia are commercially supported educational and promotional activities held in conjunction with the IASLC 2020 World Conference on Lung Cancer.

Industry Symposia

The guidelines below pertain to Industry Symposia (IS), which are defined as educational and promotional activities that are not certified for CME.

The Conference Secretariat will liaise on your behalf with the official suppliers and venue. All organizations will be responsible for the management of their own event’s logistics and for payment of costs associated with event promotion, faculty, additional audiovisual equipment, catering and staffing costs. Representatives from the Steering Committee may attend Industry Symposia to audit compliance with these guidelines.

Important Deadlines

Deadline to submit Program Draft and Faculty* July 02, 2020
Deadline to submit Menu, Minimum F&B Guarantee November 02, 2020
Deadline to submit Artwork for Delegate Bag Insert for Approval November 02, 2020
Deadline to submit Final Additional AV Requirements November 02, 2020
Deadline to submit Host/Hostess Order November 02, 2020
Deadline to submit PDF Sample of Onsite Signage November 02, 2020
Deadline to submit eBlast Banner Ad November 02, 2020
Deadline to submit Approved Artwork for Delegate Bag Insert to WCLC 2020 Printer December 01, 2020
Deadline to submit Final F&B Numbers December 04, 2020
Deadline to submit Lead Retrieval Order December 04, 2020
Deadline to submit Additional IS Staff Badges December 18, 2020
Deadline to submit Full Names for Staff Badges January 08, 2021
Singapore
Vienna
New York
San Francisco

Day 1
10:30 - 11:30 SST IS02 - Organised by AstraZeneca (Not IASLC CME Accredited)
Sponsored by
11:45 - 12:45 SST IS03 - Antibody Drug Conjugates (ADC) as Therapeutic Options for Advanced NSCLC: Opportunities and Challenges (Not IASLC CME Accredited)
Sponsored by
13:00 - 14:00 SST IS04 - Implementing Precision Oncology in the Clinic: Diagnostic Challenges and Best Practices (Not IASLC CME Accredited)
Sponsored by
14:15 - 15:15 SST IS05 - Redefining Survival Expectations in Lung Cancer (Not IASLC CME Accredited)
Sponsored by
15:30 - 16:30 SST IS06 - Novel frontiers in the treatment of NSCLC (Not IASLC CME Accredited)
Sponsored by
16:45 - 17:45 SST IS07 - Expert Perspectives on the Management of Lung Cancer (Not IASLC CME Accredited)
Sponsored by
Day 2
13:00 - 14:00 SST IS08 - What the Future Holds for Advanced NSCLC Patients with Resistance to EGFR TKIs (Not IASLC CME Accredited)
Sponsored by
13:00 - 14:00 SST IS09 - Expert Question Time: ALK+ NSCLC  (Not IASLC CME Accredited)
Sponsored by
13:00 - 14:00 SST IS10 - Thoracic Cancers, New Developments with IO (Not IASLC CME Accredited)
Sponsored by
Day 3  
13:00 - 14:00 SST IS11 - Advancing the Next Frontier of Innovation in Lung Cancer Therapies (Not IASLC CME Accredited)
Sponsored by
13:00 - 14:00 SST IS12 - Know Your Patients With NSCLC (Not IASLC CME Accredited)
Sponsored by
Day 4  
13:00 - 14:00 SST IS14 - Organised by AstraZeneca (Not IASLC CME Accredited)
Sponsored by

Day 1
03:30 - 04:30 CET IS02 - Organised by AstraZeneca (Not IASLC CME Accredited)
Sponsored by
04:45 - 05:45 CET IS03 - Antibody Drug Conjugates (ADC) as Therapeutic Options for Advanced NSCLC: Opportunities and Challenges (Not IASLC CME Accredited)
Sponsored by
06:00 - 07:00 CET IS04 - Implementing Precision Oncology in the Clinic: Diagnostic Challenges and Best Practices (Not IASLC CME Accredited)
Sponsored by
07:15 - 08:15 CET IS05 - Redefining Survival Expectations in Lung Cancer (Not IASLC CME Accredited)
Sponsored by
08:30 - 09:30 CET IS06 - Novel frontiers in the treatment of NSCLC (Not IASLC CME Accredited)
Sponsored by
09:45 - 10:45 CET IS07 - Expert Perspectives on the Management of Lung Cancer (Not IASLC CME Accredited)
Sponsored by
Day 2
06:00 - 07:00 CET IS08 - What the Future Holds for Advanced NSCLC Patients with Resistance to EGFR TKIs (Not IASLC CME Accredited)
Sponsored by
06:00 - 07:00 CET IS09 - Expert Question Time: ALK+ NSCLC  (Not IASLC CME Accredited)
Sponsored by
06:00 - 07:00 CET IS10 - Thoracic Cancers, New Developments with IO (Not IASLC CME Accredited)
Sponsored by
Day 3  
06:00 - 07:00 CET IS11 - Advancing the Next Frontier of Innovation in Lung Cancer Therapies (Not IASLC CME Accredited)
Sponsored by
06:00 - 07:00 CET IS12 - Know Your Patients With NSCLC (Not IASLC CME Accredited)
Sponsored by
Day 4  
06:00 - 07:00 CET IS14 - Organised by AstraZeneca (Not IASLC CME Accredited)
Sponsored by

Day 1
21:30 - 22:30 EST IS02 - Organised by AstraZeneca (Not IASLC CME Accredited)
Sponsored by
22:45 - 23:45 EST IS03 - Antibody Drug Conjugates (ADC) as Therapeutic Options for Advanced NSCLC: Opportunities and Challenges (Not IASLC CME Accredited)
Sponsored by
00:00 - 01:00 EST IS04 - Implementing Precision Oncology in the Clinic: Diagnostic Challenges and Best Practices (Not IASLC CME Accredited)
Sponsored by
01:15 - 02:15 EST IS05 - Redefining Survival Expectations in Lung Cancer (Not IASLC CME Accredited)
Sponsored by
02:30 - 03:30 EST IS06 - Novel frontiers in the treatment of NSCLC (Not IASLC CME Accredited)
Sponsored by
03:45 - 04:45 EST IS07 - Expert Perspectives on the Management of Lung Cancer (Not IASLC CME Accredited)
Sponsored by
Day 2
00:00 - 01:00 EST IS08 - What the Future Holds for Advanced NSCLC Patients with Resistance to EGFR TKIs (Not IASLC CME Accredited)
Sponsored by
00:00 - 01:00 EST IS09 - Expert Question Time: ALK+ NSCLC  (Not IASLC CME Accredited)
Sponsored by
00:00 - 01:00 EST IS10 - Thoracic Cancers, New Developments with IO (Not IASLC CME Accredited)
Sponsored by
Day 3  
00:00 - 01:00 EST IS11 - Advancing the Next Frontier of Innovation in Lung Cancer Therapies (Not IASLC CME Accredited)
Sponsored by
00:00 - 01:00 EST IS12 - Know Your Patients With NSCLC (Not IASLC CME Accredited)
Sponsored by
Day 4  
00:00 - 01:00 EST IS14 - Organised by AstraZeneca (Not IASLC CME Accredited)
Sponsored by

Day 1
18:30 - 19:30 PST IS02 - Organised by AstraZeneca (Not IASLC CME Accredited)
Sponsored by
19:45 - 20:45 PST IS03 - Antibody Drug Conjugates (ADC) as Therapeutic Options for Advanced NSCLC: Opportunities and Challenges (Not IASLC CME Accredited)
Sponsored by
21:00 - 22:00 PST IS04 - Implementing Precision Oncology in the Clinic: Diagnostic Challenges and Best Practices (Not IASLC CME Accredited)
Sponsored by
22:15 - 23:15 PST IS05 - Redefining Survival Expectations in Lung Cancer (Not IASLC CME Accredited)
Sponsored by
23:30 - 00:30 PST IS06 - Novel frontiers in the treatment of NSCLC (Not IASLC CME Accredited)
Sponsored by
00:45 - 01:45 PST IS07 - Expert Perspectives on the Management of Lung Cancer (Not IASLC CME Accredited)
Sponsored by
Day 2
21:00 - 22:00 PST IS08 - What the Future Holds for Advanced NSCLC Patients with Resistance to EGFR TKIs (Not IASLC CME Accredited)
Sponsored by
21:00 - 22:00 PST IS09 - Expert Question Time: ALK+ NSCLC  (Not IASLC CME Accredited)
Sponsored by
21:00 - 22:00 PST IS10 - Thoracic Cancers, New Developments with IO (Not IASLC CME Accredited)
Sponsored by
Day 3  
21:00 - 22:00 PST IS11 - Advancing the Next Frontier of Innovation in Lung Cancer Therapies (Not IASLC CME Accredited)
Sponsored by
21:00 - 22:00 PST IS12 - Know Your Patients With NSCLC (Not IASLC CME Accredited)
Sponsored by
Day 4  
21:00 - 22:00 PST IS14 - Organised by AstraZeneca (Not IASLC CME Accredited)
Sponsored by



  • Stay Connected

    Keep up to date with Conference News & Alerts.
    Sign Up

     

  • #WCLC20

© 2020 International Association for the Study of Lung Cancer – IASLC WCLC 2020 | Privacy Policy

Conference Newsletter
Subscribe to the Newsletter to receive important information about the upcoming Conference.
Thank you! We look forward to connecting soon.
Click here to close this window
Whoops, looks like there was an issue with one of the fields above - please review above.
X